Resources from the same session
650O - A phase II study of nivolumab for high-risk oral leukoplakia
Presenter: Glenn Hanna
Session: Proffered Paper session: Head & neck cancer
Resources:
Abstract
Slides
Webcast
651O - Pembrolizumab (pembro) + carboplatin (carbo) + paclitaxel (pacli) as first-line (1L) therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Phase VI KEYNOTE-B10 study
Presenter: Marcin Dzienis
Session: Proffered Paper session: Head & neck cancer
Resources:
Abstract
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session: Head & neck cancer
Resources:
Slides
Webcast
652O - Randomized phase III VANCE study: Gemcitabine and carboplatin (GC) followed by Epstein Barr virus-specific autologous cytotoxic T lymphocytes (EBV-CTL) versus the same chemotherapy as first-line treatment for advanced nasopharyngeal carcinoma (NPC)
Presenter: Han Chong Toh
Session: Proffered Paper session: Head & neck cancer
Resources:
Abstract
Slides
Webcast
653O - Neoadjuvant nivolumab (N) before chemoradiation (CRT) in high-risk HPV driven oropharynx cancer (OPC) - IMMUNEBOOST-HPV: A multicenter randomized phase II trial
Presenter: Haitham Mirghani
Session: Proffered Paper session: Head & neck cancer
Resources:
Abstract
Slides
Webcast
Invited Discussant 652O and 653O
Presenter: Lisa Licitra
Session: Proffered Paper session: Head & neck cancer
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session: Head & neck cancer
Resources:
Slides
Webcast